These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 23303333

  • 1. Efficacy and safety of the simultaneous administration of mirodenafil and an α-blocker in men with BPH-LUTS: a multicenter open-label prospective study.
    Bang WJ, Oh CY, Yoo C, Cho JS, Yang DY, Lee DH, Lee SH, Chung BH.
    Int J Impot Res; 2013; 25(4):149-54. PubMed ID: 23303333
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of combination therapy with mirodenafil and α1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study.
    Lee JY, Cho SY, Oh CY, Ha US, Lee SH, Park SY, Moon HS, Lee SW.
    Int J Impot Res; 2011; 23(6):249-56. PubMed ID: 21814227
    [Abstract] [Full Text] [Related]

  • 3. Combined tadalafil and α-blocker therapy for benign prostatic hyperplasia in patients with erectile dysfunction: a multicenter, prospective study.
    Lee JY, Park SY, Jeong TY, Moon HS, Kim YT, Yoo TK, Choi HY, Park HY, Lee SW.
    J Androl; 2012; 33(3):397-403. PubMed ID: 21868753
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS.
    Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY.
    Int J Impot Res; 2009; 21(2):122-8. PubMed ID: 19194451
    [Abstract] [Full Text] [Related]

  • 5. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L, LVHJ study team.
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [Abstract] [Full Text] [Related]

  • 7. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV, Mete UK, Mandal AK, Singh SK.
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 9. Tadalafil - a therapeutic option in the management of BPH-LUTS.
    Carson CC, Rosenberg M, Kissel J, Wong DG.
    Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW, Park NC, Lee SW, Yang DY, Park JK, Moon DG, Yang SK, Lee SW, Moon KH, Ahn TY, Kim SW, Park K, Min KS, Ryu JK, Son H, Jung J, Hyun JS.
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [Abstract] [Full Text] [Related]

  • 11. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M.
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [Abstract] [Full Text] [Related]

  • 12. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L.
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [Abstract] [Full Text] [Related]

  • 13. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
    Yan H, Zong H, Cui Y, Li N, Zhang Y.
    J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, Dey D, Viktrup L.
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M.
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of once daily administration of 50 mg mirodenafil in patients with erectile dysfunction: a multicenter, double-blind, placebo controlled trial.
    Chung JH, Kang DH, Oh CY, Chung JM, Lee KS, Kim TH, Moon KH, Lee W, Cho JM, Lee SW.
    J Urol; 2013 Mar; 189(3):1006-13. PubMed ID: 23017527
    [Abstract] [Full Text] [Related]

  • 17. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
    Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A, Ellis P.
    BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
    [Abstract] [Full Text] [Related]

  • 18. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH).
    Yu HJ, Lin AT, Yang SS, Tsui KH, Wu HC, Cheng CL, Cheng HL, Wu TT, Chiang PH.
    BJU Int; 2011 Dec; 108(11):1843-8. PubMed ID: 21592295
    [Abstract] [Full Text] [Related]

  • 19. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
    Jhang JF, Jiang YH, Kuo HC.
    Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
    [Abstract] [Full Text] [Related]

  • 20. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
    Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.
    Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.